Total Funding
12
Total FundingGrant raised
Growth Score
pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
TranquilMed develops drugs and treatments with a focus on patients suffering with restless legs syndrome.
About the Company
We have a new treatment for those suffering with Restless Legs Syndrome (RLS).
30 million people in the U.S. suffer discomfort and sleep loss due to Restless Legs Syndrome (RLS). Sufferers spend $1.5B for relatively ineffective treatments that produce side effects of nausea and vomiting. These treatments lose effectiveness over time and can make
the condition worse. TranquilMed’s new product RestEasy™ is the first treatment with no side effects available to RLS sufferers.
We have conducted studies at BYU that show 52% reduction in RLS symptoms in only 12 treatments. These studies have been accepted for publication in peer reviewed medical journals.
